Nanostructured Lipid-Based Pharmacotherapy for the Management of Psoriasis

Psoriasis, a chronic autoimmune skin disorder, poses a significant therapeutic challenge due to its complex Etiology and variable clinical manifestations. This abstract highlights recent advancements in novel carrier systems that revolutionize psoriasis management and pharmacotherapy. These innovative carriers aim to improve drug delivery, enhance therapeutic efficacy, and mitigate the adverse effects of conventional treatments. Psoriasis is characterised by hyperproliferation of keratinocytes, inflammation, and immune dysregulation. Conventional treatments often involve topical corticosteroids, phototherapy, or systemic immunosuppressants, each with its limitations, such as variable efficacy and side effects. The emergence of novel carrier systems, including liposomes, nanoparticles, and microneedle arrays, provides a promising avenue for addressing these challenges. Advanced drug delivery systems enable the precise delivery and management of the release of therapeutic agents, enhancing their penetration into the affected skin layers. Liposomal formulations, for instance, offer improved drug stability and sustained release, minimizing the need for frequent applications and reducing side effects. Nanoparticles provide a platform for encapsulating various drugs, offering enhanced solubility and bioavailability. Moreover, the integration of personalized medicine approaches into carrier design allows for tailored treatment regimens based on individual patient characteristics. This shift towards precision medicine holds the potential to optimize therapeutic outcomes and minimize adverse reactions.